epidermolysis bullosa
Information
- Disease name
- epidermolysis bullosa
- Disease ID
- DOID:2730
- Description
- "A vesiculobullous skin disease that is characterized by formation of blisters with only minor skin trauma, which can cause widespread wounds, dehydration, electrolyte abnormalities, and severe infection, frequently develops_from mutations in connective tissue elements, including genes encoding keratin, collagen, and laminin." [url:https\://rarediseases.org/rare-diseases/epidermolysis-bullosa/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04227106 | Completed | Phase 3 | Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) | January 10, 2020 | October 18, 2022 |
| NCT00004791 | Completed | Study of the Nutritional, Metabolic, and Body Composition Profile in Children and Adolescents With Epidermolysis Bullosa | August 1995 | ||
| NCT00014729 | Completed | Phase 1 | Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa | October 2000 | September 2002 |
| NCT01033552 | Completed | Phase 1/Phase 2 | Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs | January 2010 | August 12, 2021 |
| NCT01263379 | Completed | Phase 1/Phase 2 | Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa | October 5, 2010 | March 9, 2022 |
| NCT01716169 | Completed | N/A | Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care | October 2012 | November 2013 |
| NCT02014376 | Completed | Phase 2 | Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa | January 6, 2014 | June 24, 2014 |
| NCT02384460 | Completed | Phase 3 | ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa | March 11, 2015 | July 5, 2017 |
| NCT02582775 | Completed | Phase 2 | MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs | March 2016 | July 26, 2023 |
| NCT02654483 | Completed | Phase 2 | Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients | August 31, 2016 | July 27, 2018 |
| NCT02670837 | Completed | N/A | Study of Cellutome System for Treatment of Individual Lesions in EB Pts | August 4, 2016 | April 3, 2024 |
| NCT02793960 | Completed | Phase 1 | Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa | August 10, 2016 | August 26, 2019 |
| NCT03068780 | Completed | Phase 3 | Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa | March 29, 2017 | May 27, 2022 |
| NCT03158662 | Completed | Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa | April 2, 2017 | June 30, 2017 | |
| NCT03389308 | Completed | Phase 2 | Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex | December 1, 2017 | April 17, 2020 |
| NCT03730584 | Completed | N/A | Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa | February 27, 2017 | November 28, 2019 |
| NCT03836001 | Completed | Phase 2 | A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | April 18, 2019 | June 24, 2022 |
| NCT03928093 | Completed | Phase 3 | Pregabalin Treatment for RDEB Pain and Itch | August 7, 2019 | February 1, 2024 |
| NCT03942250 | Completed | N/A | Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients | January 2017 | February 2019 |
| NCT04217538 | Completed | Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa | January 4, 2017 | December 11, 2019 | |
| NCT00004761 | Completed | Establishment of the National Epidermolysis Bullosa Registry | September 1986 | ||
| NCT04644627 | Completed | Phase 1/Phase 2 | Topical Gentamicin Nonsense Suppression Therapy of EB | December 1, 2020 | May 1, 2022 |
| NCT04853667 | Completed | Improve Adherence to Weak or Strong Opioid Analgesics at the Time of Care in Children With Hereditary Epidermolysis Bullosa | April 29, 2021 | May 20, 2021 | |
| NCT05378997 | Completed | Phase 1 | Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa. | April 7, 2022 | March 16, 2024 |
| NCT00380640 | Completed | Phase 2 | The Efficacy of Trimethoprim in Wound Healing of Patients With Epidermolysis Bullosa | September 2006 | September 2007 |
| NCT00825565 | Completed | Phase 2 | Study of Alwextin® Cream in Treating Epidermolysis Bullosa | February 2009 | November 2010 |
| NCT00987142 | Completed | Phase 2 | Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa | December 2006 | May 2010 |
| NCT05533866 | Enrolling by invitation | Early Phase 1 | Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution | February 6, 2023 | December 2024 |
| NCT06330324 | Enrolling by invitation | Reproductive Options in Inherited Skin Diseases | January 1, 2024 | September 1, 2026 | |
| NCT06330350 | Recruiting | Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling | January 1, 2024 | December 31, 2025 | |
| NCT03269474 | Recruiting | Computational Drug Repurposing for All EBS Cases | November 28, 2017 | December 31, 2024 | |
| NCT05464381 | Recruiting | Phase 3 | Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over) | February 1, 2023 | December 2025 |
| NCT05725018 | Recruiting | Phase 3 | EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) | April 2, 2023 | December 1, 2024 |
| NCT05838092 | Recruiting | Phase 3 | Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) | October 18, 2023 | December 1, 2025 |
| NCT00311766 | Terminated | Phase 2 | A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa | February 2006 | November 2012 |
| NCT00478244 | Terminated | N/A | Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa | April 2007 | August 2011 |
| NCT00881556 | Terminated | Early Phase 1 | Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) | August 20, 2009 | September 2015 |
| NCT01619670 | Terminated | Phase 4 | A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa | June 2012 | January 2015 |
| NCT01749306 | Terminated | Phase 3 | A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing | December 2012 | November 2013 |
| NCT02090283 | Terminated | Phase 2 | Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa | March 26, 2014 | September 14, 2018 |
| NCT02670330 | Terminated | Phase 3 | Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa | June 9, 2015 | September 3, 2018 |
| NCT01340235 | Unknown status | Phase 3 | Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin | June 2011 | June 2012 |
| NCT05033574 | Unknown status | The State of Sexual Development in Children With Inherited Epidermolysis Bullosa | December 8, 2020 | June 1, 2023 | |
| NCT04213703 | Unknown status | A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa | March 2, 2020 | July 2023 | |
| NCT05288478 | Unknown status | Phase 2 | Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa. | April 6, 2022 | March 2023 |
| NCT01454687 | Withdrawn | N/A | Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes | October 2011 | |
| NCT00336154 | Withdrawn | Phase 4 | Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa | ||
| NCT04613102 | Withdrawn | Phase 2/Phase 3 | The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial | August 1, 2020 | December 30, 2022 |
- Disase is a (Disease Ontology)
- DOID:2731
- Cross Reference ID (Disease Ontology)
- GARD:6359
- Cross Reference ID (Disease Ontology)
- ICD10CM:Q81
- Cross Reference ID (Disease Ontology)
- MESH:D004820
- Cross Reference ID (Disease Ontology)
- NCI:C67383
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:205580008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0014527
- Exact Synonym (Disease Ontology)
- acantholysis bullosa
- ICD10 preferred id (Insert disease from ICD10)
- D0014098
- ICD10 class code (Insert disease from ICD10)
- Q81
- MeSH unique ID (MeSH (Medical Subject Headings))
- D004820